当前位置: 首页 >> 检索结果
1. Sirolimus-Eluting Balloon With Provisional Stenting Versus Systematic Drug-Eluting Stent Implantation to Treat De Novo Coronary Lesions: A Randomized, Open-Label, Noninferiority Trial.
作者: Christian Spaulding.;Florian Krackhardt.;Kris Bogaerts.;Eltigani Abdelaal.;Fernando Alfonso.;Carlo Briguori.;Leonhard Bruch.;Nicholas Cruden.;Alexander W Den Hartog.;Philippe Garot.;Mathieu Godin.;David Hildick-Smith.;Thomas Johnson.;Andrew Ladwiniec.;Axel Linke.;Clint Anthony Maart.;Kambis Mashayekhi.;Pascal Meier.;Ludovic Meunier.;Kenneth Morgan.;Peter O'Kane.;Etienne Puymirat.;Tuomas T Rissanen.;Manel Sabaté.;Thomas Schmitz.;Gabor G Toth.;Jasper Trevelyan.;Piotr Wanczura.;Marcus Wiemer.;Joanna J Wykrzykowska.;Philip Urban.;Simon Eccleshall.; .
来源: Circulation. 2026年154卷3期185-197页
Implantation of drug eluting stents (DESs) is currently the default approach for percutaneous coronary interventions, but long-term adverse events still exist. An approach with minimal stenting deserves to be assessed in a randomized trial. We studied a novel sirolimus-eluting balloon (SEB) that elutes sirolimus over a 90-day period using a biodegradable polymer microreservoir technology.
2. Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials.
作者: Hadar Klein.;Liav Alufer.;Dana Tamar Goldberg Toren.;Dafna Pachter.;Omer Kamer.;Noa Ebstein Karamani.;Yoash Chassidim.;Ilan Shelef.;Assaf Rudich.;Uri Yoel.;Gal Ben-Arie.;Hila Zelicha.;Anat Yaskolka Meir.;Gal Tsaban.;Carmi Bartal.;Matthias Blüher.;Michael Stumvoll.;Uta Ceglarek.;Berend Isermann.;Lu Qi.;Meir J Stampfer.;Frank B Hu.;Iris Shai.
来源: Circulation. 2026年154卷1期16-27页
During the 18-month CENTRAL (Effect of Weight-Loss Diet Strategies and Exercise on Dynamics of Body Fat Depots and Metabolic Rate) and DIRECT-PLUS (Dietary Intervention Randomized Controlled Trial Polyphenols Unprocessed) randomized controlled trials, participants achieved considerable reductions in abdominal and ectopic fat. We examined the long-term postintervention cardiometabolic profile associated with these changes.
3. Pulsed Field Ablation Versus Sham to Treat Atrial Fibrillation: The PFA-SHAM Randomized Clinical Trial.
作者: Pavel Osmancik.;Petr Neuzil.;Jana Hozmanova.;Jan Petru.;Dalibor Herman.;Stepan Kralovec.;Marek Hozman.;Marko Tichy.;Petr Waldauf.;Tomas Karel.;Lucie Sediva.;Jakub Fischer.;Lubomir Stepanek.;Ivana Mala.;Veronika Lekesova.;Pavel Hala.;Moritoshi Funasako.;Jana Vesela.;Vera Filipcova.;Jakub Karch.;William Whang.;Vivek Y Reddy.
来源: Circulation. 2026年153卷25期1984-1998页
Catheter ablation for atrial fibrillation (AF) is one of the most common cardiovascular procedures being performed worldwide. Despite the large body of evidence of its effectiveness, with a single exception, prior ablation studies were largely unblinded trials. Accordingly, residual concerns remained about placebo effects, both for AF recurrence and, in particular, on subjective outcomes such as quality of life or anxiety. Here, we compared pulsed field ablation (PFA) with a sham procedure to treat patients with symptomatic AF.
4. Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.
作者: Victorien Monguillon.;Nicholas A Marston.;Erin A Bohula.;Jeong-Gun Park.;Julia F Kuder.;Sabina A Murphy.;Gaetano M De Ferrari.;Lawrence A Leiter.;Jose C Nicolau.;Christoph Ebenbichler.;Peter Sinnaeve.;Assen Goudev.;Andrzej Budaj.;Oleg Averkov.;Lale Tokgözoğlu.;Ron Blankstein.;Dragos Vinereanu.;Robert P Giugliano.;Marc S Sabatine.;Michelle L O'Donoghue.
来源: Circulation. 2026年153卷25期1960-1968页
Lp(a) (lipoprotein[a]) is a risk factor for coronary heart disease. Whether baseline Lp(a) identifies higher-risk patients who derive more benefit from evolocumab is not established in a population without previous myocardial infarction (MI) or stroke.
5. Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial.
作者: Brian A Bergmark.;Erin A Bohula.;Nicholas A Marston.;Jeong-Gun Park.;Julia F Kuder.;Sabina A Murphy.;Gaetano De Ferrari.;Lawrence A Leiter.;Jose C Nicolau.;Oleg Averkov.;Min-Ji Charng.;Christoph Ebenbichler.;Andrejs Erglis.;Ioanna Gouni-Berthold.;Gilles Montalescot.;Stephen J Nicholls.;Axel Sigurdsson.;Peter R Sinnaeve.;Rimvydas Slapikas.;Konstantinos Tsioufis.;Subodh Verma.;Margus Viigimaa.;Ajay Bhatia.;Lily Xin.;Emileigh Walsh.;E Magnus Ohman.;Robert P Giugliano.;Marc S Sabatine.
来源: Circulation. 2026年154卷1期28-36页
The clinical benefit of intensive LDL cholesterol (LDL-C) lowering with evolocumab in patients with prior percutaneous coronary intervention (PCI) but without a prior myocardial infarction (MI) is not established.
6. Resuscitation From Out-of-Hospital Cardiac Arrest: When Is EtCO2 Reliably Associated With ROSC?
作者: Michelle M J Nassal.;Rachel M Smith.;Elisabete Aramendi.;Andoni Elola.;Xabier Jaureguibeitia.;Ahamed H Idris.;Mohamud R Daya.;Jestin N Carlson.;Tom P Aufderheide.;Graham Nichol.;Ashish R Panchal.;Henry E Wang.
来源: Circulation. 2026年154卷2期88-95页
Exhaled end-tidal carbon dioxide (EtCO2) trajectory is associated with out-of-hospital cardiac arrest (OHCA) outcomes. However, the minimum EtCO2 monitoring duration needed to discriminate return of spontaneous circulation (ROSC) from non-ROSC remains unknown. We sought to determine the EtCO2 trajectory observation time required to differentiate ROSC from non-ROSC patients.
7. Comparative Efficacy of Transfusion Strategies in Women and Men With Myocardial Infarction and Anemia: Prespecified Secondary Findings From the MINT Trial.
作者: J Dawn Abbott.;Jocelyne R Benatar.;Colleen M Ballantyne.;Alice K Jacobs.;Andrew M Goldsweig.;Dean A Fergusson.;Brandon M Hebert.;Marnie Bertolet.;Tabassome Simon.;P Gabriel Steg.;Shaun G Goodman.;Harvey D White.;Jeffrey L Carson.;Maria M Brooks.; .
来源: Circulation. 2026年154卷3期201-211页
The optimal transfusion strategy in patients with acute myocardial infarction (AMI) and anemia may be influenced by sex differences in pathophysiology and cardiovascular outcomes. The Myocardial Ischemia and Transfusion trial (MINT) randomized patients with AMI and anemia to restrictive or liberal transfusion thresholds, but sex-stratified outcomes remain undefined. The objective was to evaluate whether the clinical effect of restrictive versus liberal red blood cell transfusion strategies differs by sex in patients hospitalized with AMI and anemia.
8. Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.
作者: Rick B Vega.;Gavin O'Mahony.;April M Barbour.;Hongtao Yu.;Jane Knöchel.;Johan Brengdahl.;Thomas Hochdörfer.;Linnéa Bergenholm.;Eva Töppner Carlsson.;Andrea Ahnmark.;Christina Rye Underwood.;Anna Rudvik.;Debra Carter.;Johanna Laru.;Aspen Gutgsell.;Lee Twaddle.;Pavlo Garkaviy.;Anna Bogstedt.;Eva Hurt-Camejo.;Tasso Miliotis.;Maria Ryaboshapkina.;Andreas Hober.;Brian Hubbard.;Michael Serrano-Wu.;Virendar Kaushik.;Stefan Geschwindner.;Michael C McCarthy.;Daniel Lindén.;Jaya B Rosenmeier.
来源: Circulation. 2026年153卷25期1999-2010页
Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is an effective therapy for reducing low-density lipoprotein (LDL) cholesterol (LDL-C) in adults with hyperlipidemia, including heterozygous familial hypercholesterolemia, thereby lowering cardiovascular risk. Current PCSK9 inhibitors are injectable therapies; no oral small-molecule PCSK9 inhibitor has yet been approved.
9. Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial.
作者: Sebastiaan Dhont.;Sara Moura Ferreira.;Xavier Galloo.;Pieter Martens.;Evelyne Meekers.;Katrien Tartaglia.;Sébastien Deferm.;Lieven Herbots.;Wilfried Mullens.;Frederik H Verbrugge.;Jan Verwerft.;Philippe B Bertrand.
来源: Circulation. 2026年153卷25期1973-1983页
Atrial functional mitral regurgitation (AFMR) characterizes a high-risk phenotype in heart failure with preserved ejection fraction (HFpEF). Although sacubitril/valsartan reduces functional mitral regurgitation (MR) in HF with reduced EF (HFrEF), its impact on exercise hemodynamics and the dynamic burden of AFMR in HFpEF remains to be elucidated.
10. Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.
作者: Ahmad Masri.;Francesco Cappelli.;Margot K Davis.;Marianna Fontana.;Pablo Garcia-Pavia.;Julian D Gillmore.;Mazen Hanna.;Laura Obici.;Scott D Solomon.;Brett W Sperry.;Nobuhiro Tahara.;Márcia Waddington-Cruz.;Arnt V Kristen.;Rodney H Falk.;Sanjiv J Shah.;Jose Nativi-Nicolau.;Nicholas J Viney.;Qingqing Yang.;Jersey Chen.;Sotirios Tsimikas.;Mathew S Maurer.
来源: Circ Heart Fail. 2026年19卷6期e014205页
Transthyretin amyloidosis with cardiomyopathy is a progressive, fatal disease characterized by deposition of extracellular misfolded transthyretin (TTR) in the myocardium. Eplontersen is an N-acetylgalactosamine ligand-conjugated antisense oligonucleotide targeting hepatocyte TTR messenger RNA to reduce the production of circulating TTR.
11. Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study.
作者: Fiyyaz Ahmed-Jushuf.;Michael J Foley.;Shayna Chotai.;Christopher A Rajkumar.;Danqi Wang.;Florentina A Simader.;Krzysztof Macierzanka.;Kayla Chiew.;Sannidhya Misra.;Rupert Williams.;Klio Konstantinou.;Jehangir N Din.;Shah R Mohdnazri.;Peter D O'Kane.;Peter Haworth.;Sukhjinder S Nijjer.;Henry Seligman.;Thomas R Keeble.;John R Davies.;Gerald Clesham.;Jonathan Hinton.;James C Spratt.;Jason N Dungu.;Daniel Knight.;Tushar Kotecha.;Frank E Harrell.;James P Howard.;Darrel P Francis.;Matthew J Shun-Shin.;Rasha K Al-Lamee.
来源: Circulation. 2026年153卷23期1795-1812页
In stable coronary artery disease, the primary goal of percutaneous coronary intervention (PCI) is symptom relief. Fractional flow reserve (FFR) and nonhyperemic pressure ratios such as resting full-cycle ratio (RFR) are used to guide revascularization. Although these indices correlate with myocardial ischemia, they have never been validated against the onset of angina. The physiological thresholds for angina, FFRangina and RFRangina, angina (FFRangina at rest and during exercise remain undefined.
12. Subcutaneous Defibrillator Implantation With or Without Defibrillation Test: The Primary Results of the Randomized PRAETORIAN-DFT Trial.
作者: Reinoud E Knops.;Christelle Marquie.;Peter Nordbeck.;Roland R Tilz.;Leonard A Dijkshoorn.;Anne-Floor B E Quast.;Tom F Brouwer.;Pier D Lambiase.;Christopher J Cassidy.;Lucas V A Boersma.;Martin C Burke.;Timothy R Betts.;Vincent Probst.;Harish Manyam.;Frank A L E Bracke.;Hendrik Bonnemeier.;Jürgen Kuschyk.;Gregory Golovchiner.;Anouk de Weger.;Marc A Miller.;Jonas S S G de Jong.;Abdul Ghani.;Nigel Lewis.;Eloi Marijon.;Nick R Bijsterveld.;Pascal Defaye.;Claire A Martin.;Duncan C Field.;Jan Elders.;Naushad A Shaik.;Serge Boveda.;Willeke van der Stuijt.;Jolien A de Veld.;Kirsten M Kooiman.;Shari Pepplinkhuizen.;Lukas Kaiser.;Anita Arya.;Raymond Tukkie.;Léon J P M van Woerkens.;Margriet W Feenema-Aardema.;Michael Glikson.;Alexander H Maass.;Amir Zaidi.;Arthur A M Wilde.;Louise R A Olde Nordkamp.;Lonneke Smeding.;Mikhael F El-Chami.; .
来源: Circulation. 2026年154卷6期520-531页
To improve survival of patients at risk of sudden cardiac death, subcutaneous implantable cardioverter defibrillators (S-ICDs) require optimal implant positioning for effective shocks. Defibrillation (DF) testing is recommended but carries serious risks. The PRAETORIAN score predicts defibrillation outcomes on the basis of chest X-ray. The PRAETORIAN-DFT (Prospective Randomized Comparative Trial of Subcutaneous Implantable Cardioverter Defibrillator Implantation With and Without Defibrillation Testing) trial evaluated whether omission of DF testing guided by the PRAETORIAN score is noninferior for first-shock efficacy.
13. Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure.
作者: Deepak K Gupta.;Lynne W Stevenson.;Erica M Garner.;Christopher Maulion.;Hui Nian.;Patricia R Wright.;Adina F Turcu.;Shouzou Wei.;Nancy J Brown.
来源: Circ Heart Fail. 2026年19卷6期e014117页
Symptomatic hypotension can limit sacubitril/valsartan therapy. Neprilysin inhibition may augment vasodilators, such as bradykinin. We hypothesized that bradykinin contributes to blood pressure (BP) lowering with sacubitril/valsartan in stable ambulatory patients with heart failure and reduced ejection fraction <50%.
14. Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana.
作者: Fred Stephen Sarfo.;Albert Akpalu.;Ansumana S Bockarie.;Samuel Blay Nguah.;Nana Kwame Ayisi-Boateng.;Rexford Adu Gyamfi.;Agnes Amankwaah Arthur.;Christiana Duah.;Timothy Fiattor.;Kwadwo Gyebi Agyenim-Boateng.;Emmanuel Achab.;Lambert Tetteh Appiah.;Priscilla Abrafi Opare-Addo.;Sheila Adamu.;Manolo Agbenorku.;Nathaniel Adusei-Mensah.;Raelle Tagge.;Michael Ampofo.;Shadrack Osei Asibey.;Ruth Laryea.;Evans MacCready.;Victoria Aba Sam.;Kwaku Affrim Buadu.;Solomon Adu.;Nyantakyi Adu Darko.;Melvin Agbogbatey.;John H Amuasi.;Bruce Ovbiagele.
来源: Circulation. 2026年153卷24期1890-1902页
Addressing the rising burden of stroke in low-income countries will require pragmatic and scalable interventions targeting major risk factors. Under routine care settings, <10% of adults living with hypertension ever achieve blood pressure control, accentuating risks for adverse vascular events. The effectiveness of mobile health-centered, nurse-led interventions for the control of hypertension among patients with recent stroke in a resource-limited African setting is unknown.
15. Optimal Ablation Strategies for Persistent Atrial Fibrillation With Heart Failure: Three-Year Follow-Up of a Prospective Multicenter Randomized Trial.
作者: Kaige Li.;Xinhua Wang.;Mu Qin.;Ping Ye.;Bing Han.;Weifeng Jiang.;Yu Zhang.;Qidong Zheng.;Anjing Ji.;Menghe Zhang.;Yanzhe Wang.;Shaohui Wu.;Kai Xu.;Changhao Xu.;Xu Liu.;Xumin Hou.
来源: Circ Arrhythm Electrophysiol. 2026年19卷4期e014394页
Catheter ablation has been shown to improve prognosis in patients with heart failure (HF) and atrial fibrillation (AF); however, the optimal ablation strategy remains undefined.
16. Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.
作者: Nicholas A Marston.;Brian A Bergmark.;Thomas A Prohaska.;Filipe A Moura.;André Zimerman.;Veronica J Alexander.;Yu Mi Kang.;Julia Weinland.;Xinhui Ran.;Sabina A Murphy.;Shuanglu Zhang.;Dan Li.;Maciej Banach.;Erik S G Stroes.;Robert Kiss.;Daniel Gaudet.;Michal Vrablik.;Assen Goudev.;Jeroen J Bax.;Matthew J Budoff.;Borek Foldyna.;Michael T Lu.;Sotirios Tsimikas.;Robert P Giugliano.;Marc S Sabatine.
来源: Circulation. 2026年153卷20期1539-1548页
Whether lowering triglyceride-rich lipoproteins and remnant cholesterol favorably modifies coronary atherosclerosis is unclear. Olezarsen, an antisense oligonucleotide that targets apolipoprotein C-III, reduces triglycerides by ~60% and remnant cholesterol by ~70%, has a neutral effect on LDL (low-density lipoprotein) cholesterol (LDL-C), and reduces apoB (apolipoprotein B) by ~15% in moderate hypertriglyceridemia. We investigated the effect of olezarsen on coronary plaque in adults with largely moderate hypertriglyceridemia.
17. Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN-STEMI Randomized Controlled Trial.
作者: Misa Fister.;Marko Noc.;Peter Radsel.;Matjaz Bunc.;Danilo Franco.;Tomaz Goslar.; .
来源: Circulation. 2026年153卷20期1526-1534页
Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for patients with ST-segment-elevation myocardial infarction (STEMI). We investigated the benefits and safety of pretreatment with unfractionated heparin (UFH) in patients with STEMI referred to primary PCI.
18. Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Noninferiority Randomized Trial.
作者: Mauro Biffi.;Giovanni Rovaris.;Ennio Carmine Luigi Pisanò.;Valeria Calvi.;Antonio Rapacciuolo.;Matteo Santamaria.;Giampiero Maglia.;Gabriele Zanotto.;Emanuele Bertaglia.;Gerardo Nigro.;Andrea Giomi.;Francesca Notarangelo.;Patrizia Pepi.;Giuliano D'Alterio.;Davide Castagno.;Antonio Dello Russo.;Antonino Nicosia.;Massimo Zecchin.;Matteo Bertini.;Antonio Duca.;Daniele Giacopelli.;Alessio Gargaro.;Giovanni Luca Botto.; .
来源: Circulation. 2026年153卷22期1707-1718页
The role of atrial pacing support is unclear in patients receiving cardiac resynchronization therapy-defibrillator (CRT-D) without sinus node dysfunction.
19. Sotatercept for Combined Post- and Precapillary Pulmonary Hypertension Associated With Heart Failure: Results From the Phase 2, Randomized, Placebo-Controlled CADENCE Study.
作者: Mardi Gomberg-Maitland.;Ryan J Tedford.;David Langleben.;Stephan Rosenkranz.;Barry Miller.;Aaron D Jones.;Alessia Urbinati.;Ciaran J McMullan.;Alexandra G Cornell.;Jean-Luc Vachiery.
来源: Circulation. 2026年153卷19期1446-1459页
Combined post- and precapillary pulmonary hypertension in heart failure with preserved ejection fraction involves remodeling in both the heart and pulmonary vasculature. Despite significant mortality, there are no proven therapies.
20. Combined Anatomic and Functional Testing Identifies Patients With Obstructive Coronary Artery Disease Who Benefit From Revascularization.
作者: Oliver Buchhave Pedersen.;Laust Dupont Rasmussen.;Jacob Hartmann Søby.;Lars C Gormsen.;Evald Høj Christiansen.;Juhani Knuuti.;Morten Bøttcher.;Leslee Shaw.;Simon Winther.
来源: Circ Cardiovasc Imaging. 2026年19卷4期e019267页
In patients with obstructive coronary artery disease, early revascularization does not improve outcomes but may reduce angina symptoms. The objective of this study was to examine whether changes in health status outcomes following revascularization are explained by the extent of myocardial perfusion defects and improvement in myocardial perfusion.
|